Is Nippon India ETF S&P BSE Sensex Next 50 halal to invest in?

As of September 2026, Nippon India ETF S&P BSE Sensex Next 50 542747.BO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Nippon India ETF S&P BSE Sensex Next 50 a Shariah-compliant ETF?

An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes Nippon India ETF S&P BSE Sensex Next 50 using these criteria to determine its compliance status.

How often is the Shariah compliance for Nippon India ETF S&P BSE Sensex Next 50 updated?

The Shariah compliance status of Nippon India ETF S&P BSE Sensex Next 50 may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.

Can a halal ETF like Nippon India ETF S&P BSE Sensex Next 50 become non-compliant?

Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.

Where can I check the Shariah status of Nippon India ETF S&P BSE Sensex Next 50?

You can check the latest Shariah compliance status of Nippon India ETF S&P BSE Sensex Next 50 on Musaffa's ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.

Nippon India ETF S&P BSE Sensex Next 50 542747.BO

542747.BO Shariah Compliance

Screening Methodology: AAOIFI

As of September 2026, Nippon India ETF S&P BSE Sensex Next 50 is classified as not halal.

NOT HALAL

Is Nippon India ETF S&P BSE Sensex Next 50 Halal?

Shariah Compliance Analysis of 542747.BO ETF

IN Equity Large Cap

No. As of September 2026, Nippon India ETF S&P BSE Sensex Next 50 (542747.BO) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Nippon India ETF S&P BSE Sensex Next 50 does not pass Musaffa's business and financial screening criteria.

542747.BO was created on 2019-07-30 by Nippon. The fund's investment portfolio concentrates primarily on large cap equity. The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the S&P BSE SENSEX Next 50 Index before expenses, subject to tracking errors.

Nippon India ETF S&P BSE Sensex Next 50 (542747.BO) Chart

Key Statistics of Nippon India ETF S&P BSE Sensex Next 50 (542747.BO)

Today's Open

AUM

Avg. Volume

Expense Ratio

P/E Ratio

P/B Ratio

FAQ's for Nippon India ETF S&P BSE Sensex Next 50 (542747.BO)

As of September 2026, Nippon India ETF S&P BSE Sensex Next 50 542747.BO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes Nippon India ETF S&P BSE Sensex Next 50 using these criteria to determine its compliance status.
The Shariah compliance status of Nippon India ETF S&P BSE Sensex Next 50 may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.
Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.
You can check the latest Shariah compliance status of Nippon India ETF S&P BSE Sensex Next 50 on Musaffa’s ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.